The success of Sildenafil initially fueled a period of growth for pharma, however recent changes present a murky outlook for shareholders. Generic versions are eroding earnings, and persistent legal battles add further https://lewysnjcx075468.dsiblogger.com/74260183/the-blue-pill-and-pharma-a-precarious-investment